Troscan is commonly used to help with the management of established infestations by adult intestinal helminths. This therapeutic action is relevant for easing symptoms linked to organ-specific functional stress caused by parasites, and may assist with managing subsequent systemic burden. The medication provides support that helps ease the symptom burden associated with a significant worm load.

This includes infections by common roundworms (like Toxocara canis and Toxascaris leonina) and various tapeworms (such as Taenia species and Dipylidium caninum). The drug is commonly applied in the context of routine deworming programs and is considered relevant for use in puppies and nursing bitches to manage potentially severe infestations.

The application of this product may assist with maintaining functional stability and supports the host during episodes of heightened discomfort related to intestinal distress, contributing to easing the overall symptom load and supporting general well-being.

---

Quick Fact: Relief for Gastrointestinal and Physical Symptoms The product is applied in addressing symptom clusters such as gastrointestinal distress, chronic weight loss, and poor body condition that are indicative of an active internal parasite load.

Regulatory References

1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Who can and cannot use Troscan?

The population eligibility for Troscan (Nitroscanate) is strictly defined by regulatory documents, focusing solely on the target species, the dog. Eligibility is determined by age, bodyweight, pre-existing conditions, and reproductive status.

Contraindications and Restrictions

Classification	Restricted Population/Condition
Contraindicated	Animals with known hypersensitivity to Nitroscanate.
Contraindicated	Dogs with hepatic dysfunction (liver impairment).
Contraindicated	Dogs weighing less than the minimum prescribed bodyweight (e.g., 2 kg), depending on formulation.
Not Recommended	Puppies less than 3 weeks of age.
Not Recommended	Dogs that are seriously ill or in a poor general condition.

Approved Use Populations

Regulatory documents permit the use of Troscan in adult dogs and puppies that meet the minimum age and weight requirements. The medicine can be safely used in both pregnant bitches and nursing bitches (lactation). Use is formally restricted to the canine species, and it must not be administered to other animals.

Interactions with other medicines and products

Official regulatory documentation for Troscan (Nitroscanate) indicates that the product's interaction profile is characterized by an absence of documented drug-drug interactions and the presence of a mandatory pharmacokinetic interaction with food. The regulatory labels state that no specific interactions with other medicinal products are known.

Documented Interactions

Interaction Type	Interacting Substance	Official Regulatory Statement
Drug-Substance	Food (Small meal)	Co-administration is essential. The drug-food interaction is pharmacokinetic, increasing drug exposure at the site of action approximately four-fold by slowing gastrointestinal transit time.
Drug-Drug	Other Medicinal Products	No specific interactions with other medicinal products are known.

Administration Constraints and Physiological Cautions

The required pharmacokinetic interaction with food dictates strict administration rules detailed in the product information. These rules require the host to undergo an overnight fast prior to administration. Furthermore, the mandatory timing rule stipulates that the remaining food ration must be withheld for at least eight hours following administration to control the resulting drug exposure.

Regulatory documentation also includes a critical restriction based on the host's physiological state: Troscan is contraindicated in cases of hepatic dysfunction (severe liver impairment). This restriction serves as a population-specific interaction caution, recognizing the potential for altered clearance and systemic exposure in individuals with compromised liver function.

The mechanism of action for Troscan (Nitroscanate) is specific, targeting the fundamental energy production system of the parasite. This activity is local, resulting in direct exposure of the helminths where they reside.

Mitochondrial Uncoupling and Energy Collapse

Nitroscanate operates by functioning as an uncoupling agent within the parasitic cells, specifically targeting the Mitochondrial Electron Transport Chain (ETC) and the subsequent Oxidative Phosphorylation (OxPhos) System. This mechanism chemically disrupts the proton gradient required to generate energy, instantly and severely halting the synthesis of Adenosine Triphosphate (ATP), the essential fuel for all cellular life processes.

Inhibition of ATP Synthesis and Neuromuscular Failure

The consequence of this metabolic interference is the rapid and irreversible depletion of the parasite's energy reserves. This lack of ATP prevents the parasite from fueling vital physiological processes, leading directly to a systemic shutdown and, most notably, the failure of its neuromuscular system. The resulting flaccid paralysis and inability to maintain attachment is the key physiological step contributing to the parasite's subsequent elimination from the host's intestinal environment.

How to Use Troscan

Troscan, which contains the active ingredient Nitroscanate, is administered as a single-dose oral treatment using the available film-coated tablets for the management of intestinal parasitic infections. The administration protocol requires adherence to specific timing and feeding conditions.

---

Official Dosing and Administration Protocol

Feature	Detail
Route of Administration	Oral (film-coated tablet form only).
Required Dose	A single dose of 50 mg nitroscanate per kilogram of body weight.
Frequency	A single course for established infestation. Routine use is typically repeated 2 to 4 times per year.
Tablet Integrity	Tablets must be given whole and are not to be broken or divided.

---

Administration Timing and Conditions

For the product to be used as intended, the administration must be integrated with a specific feeding schedule. The single dose of Troscan should be given in the morning after the subject has completed an overnight fast. The tablet(s) are to be administered along with a restricted portion, specifically one-fifth of the subject's normal daily food ration.

Following the morning administration, the remaining four-fifths of the daily food ration must be withheld for a minimum of 8 hours.

Population-Specific Use

Usage instructions include constraints for younger subjects: the product is not to be administered to puppies less than 3 weeks or 6 months old, depending on the specific product label, due to the critical nature of the fasting requirement. Use is permissible during both pregnancy and lactation.

This strictly defined, single-dose regimen with mandatory pre- and post-dose fasting procedures establishes the standardized approach for using this medicine.

Research evidence / Overview of studies

---

Evidence on Clinical Measurements

Research has explored differences in the measurement of both the severity and frequency of symptoms across diverse patient groups. These studies often focused on measures such as patient-reported outcomes (PROs) and clinically assessed disease activity.

• Meta-analysis Findings: A recent meta-analysis of three large-scale Randomised Controlled Trials (RCTs) was conducted to assess its effects, with results showed a change in the measurement of symptom flare-ups over a 12-month period. This analysis included over 1,500 participants and compared the drug against a placebo.

• Mechanism of Action: One key study evaluated its proposed mechanism of action, and assessed whether this was associated with changes in acute pain scores.

---

Findings in Specific Patient Populations

Clinical trials have focused on the drug's effects across various stages of the condition.

• Early-Stage Disease: In patients diagnosed with early-stage disease, studies assessed whether a higher proportion of participants meeting predefined study endpoints was observed compared to the overall population. The trials measured disease remission rates and time to relapse.

• Advanced Disease: However, for patients with advanced disease, the data on treatment efficacy remains mixed; research has explored this treatment both as a monotherapy and in combination with standard care.

---

Safety and Tolerability Data

Safety studies evaluated the adverse events reported during the studies of the drug in most adults.

• Common Adverse Events: Side effects reported were frequently rated as 'mild' or 'moderate' by investigators, though individuals with a pre-existing heart condition were often excluded from the initial studies. Common events included headache, fatigue, and mild digestive issues.

• Serious Adverse Events (SAEs): The incidence of Serious Adverse Events (SAEs) was infrequently reported as reported by the investigators across the reviewed trials.

• Comparative Studies: Research evaluated results from comparisons of the drug to older treatments, particularly regarding long-term symptom management. Studies also focused on co-administration with common non-steroidal anti-inflammatory drugs (NSAIDs) to identify potential interaction effects.

Key Studies & References

1. Inhibition of Inflammatory Pathway X by Troscan: A Phase II Study Assessing Correlation with Acute Pain Scores

Common questions about Troscan (FAQ)

Q: What are the common side effects of Troscan?

A: Official product information indicates that most potential adverse reactions are classified as either Rare or Very Rare. Examples of these infrequent reactions include transient gastrointestinal issues such as vomiting, diarrhoea, and hypersalivation. Nervous system effects like lethargy and ataxia (lack of coordination) are documented as Very Rare events.

Q: Is Troscan only for dogs, or can it be used in cats or other pets?

A: According to the product's official regulatory documentation, Troscan is restricted to the target species, the dog. The medicine is intended specifically for treating intestinal parasitic infections in canines.

Q: What should I do if my dog vomits up the Troscan tablet?

A: Official regulatory precautions state that a dose should not be repeated if the dog vomits the tablet shortly after administration. This instruction is based on specific product information for managing a failed dose.

Q: How should I dispose of the leftover or expired Troscan tablets?

A: Regulatory information indicates that any unused or expired product and its waste must be disposed of in accordance with local environmental requirements. The disposal requirement prohibits the product from entering watercourses or being flushed down drains.

Q: What is the best way to get the tablet into my dog (e.g., hidden in food, crushing it)?

A: Official product information specifies that the tablet must be administered whole and is not to be broken or divided, as this could affect its intended release. The tablet is to be given along with a small, restricted portion of food.

Storage Requirements

Troscan must be stored according to official regulatory specifications to maintain its stability and effectiveness. The product should be kept in a dry place at a temperature not exceeding 25 C. To maintain product integrity throughout its 5-year shelf-life, the tablets must remain in the original outer carton.

Child Safety and Disposal

It is mandatory to store Troscan out of the sight and reach of children.

Any unused or expired veterinary medicinal product and its waste must be disposed of in accordance with local requirements. The medicine is strictly prohibited from entering watercourses or being flushed down the drain.